Maze Therapeutics Inc.

NASDAQ: MAZE · Real-Time Price · USD
13.37
0.02 (0.15%)
At close: Aug 15, 2025, 3:06 PM

Maze Therapeutics Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022
Revenue
167.5M n/a n/a
Cost of Revenue
3.3M 4.09M 3.82M
Gross Profit
167.5M -4.09M -3.82M
Operating Income
57.59M -98.55M -111.03M
Interest Income
4.65M 1.97M 2.03M
Pretax Income
53.4M -100.42M -114.94M
Net Income
52.23M -100.42M -114.94M
Selling & General & Admin
26.42M 24.61M 22.83M
Research & Development
83.5M 73.94M 88.19M
Other Expenses
n/a n/a n/a
Operating Expenses
109.91M 98.55M 111.03M
Interest Expense
n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a
Cost & Expenses
109.91M 98.55M 111.03M
Income Tax Expense
1.17M n/a n/a
Shares Outstanding (Basic)
43.8M 43.78M 43.78M
Shares Outstanding (Diluted)
43.8M 43.78M 43.78M
EPS (Basic)
0.08 -2.29 -2.63
EPS (Diluted)
0.08 -2.29 -2.63
EBITDA
60.88M -94.46M -107.21M
EBIT
57.59M -98.55M -111.03M
Depreciation & Amortization
3.3M 4.09M 3.82M